Prognostic Value of Lymph Node Density in Patients With T3 and T4 Pyriform Sinus Carcinoma.
prognostic factor
pyriform sinus
recurrence
squamous cell carcinoma
survival
Journal
Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941
Informations de publication
Date de publication:
Historique:
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
30
11
2021
Statut:
ppublish
Résumé
Lymph node density is a parameter used to more accurately predict tumor recurrence and patient survival. However, its association with surgical outcome in pyriform sinus carcinoma remains unclear. The purpose of this study was to assess the prognostic value of lymph node density in advanced pyriform sinus carcinoma. A total of 87 patients with pyriform sinus carcinoma treated between 2008 and 2015 were enrolled. Then, 5-year overall survival, 5-year disease-specific survival, 5-year disease-free survival, and 5-year regional recurrence-free survival were utilized to assess the prognostic significance of lymph node density. With a median follow-up period of 31.8 months, 5-year overall survival, disease-specific survival, disease-free survival, and regional recurrence-free survival were 37.9%, 46.0%, 41.4%, and 54.0%, respectively. Univariate analysis revealed that lymph node density ≥ 0.093 was a significant predictor of poor 5-year overall survival ( Taken together, these results reveal that lymph node density is a powerful prognostic factor for patients with T3 and T4 pyriform sinus carcinoma, and the median lymph node density cutoff values ≥ 0.093 are associated with a greater risk of recurrence and poorer survival.
Sections du résumé
BACKGROUND/AIM
Lymph node density is a parameter used to more accurately predict tumor recurrence and patient survival. However, its association with surgical outcome in pyriform sinus carcinoma remains unclear. The purpose of this study was to assess the prognostic value of lymph node density in advanced pyriform sinus carcinoma.
PATIENTS AND METHODS
A total of 87 patients with pyriform sinus carcinoma treated between 2008 and 2015 were enrolled. Then, 5-year overall survival, 5-year disease-specific survival, 5-year disease-free survival, and 5-year regional recurrence-free survival were utilized to assess the prognostic significance of lymph node density.
RESULTS
With a median follow-up period of 31.8 months, 5-year overall survival, disease-specific survival, disease-free survival, and regional recurrence-free survival were 37.9%, 46.0%, 41.4%, and 54.0%, respectively. Univariate analysis revealed that lymph node density ≥ 0.093 was a significant predictor of poor 5-year overall survival (
CONCLUSION
Taken together, these results reveal that lymph node density is a powerful prognostic factor for patients with T3 and T4 pyriform sinus carcinoma, and the median lymph node density cutoff values ≥ 0.093 are associated with a greater risk of recurrence and poorer survival.
Identifiants
pubmed: 32875969
doi: 10.1177/1533033820945806
pmc: PMC7476345
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533033820945806Références
Eur Arch Otorhinolaryngol. 2016 Dec;273(12):4595-4600
pubmed: 27372745
Eur Arch Otorhinolaryngol. 2016 May;273(5):1261-7
pubmed: 25784183
J Clin Oncol. 2008 Jan 1;26(1):121-6
pubmed: 18165646
Anticancer Res. 2018 Aug;38(8):4877-4882
pubmed: 30061263
Ann Surg Oncol. 2017 Jun;24(6):1707-1713
pubmed: 28130622
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1014-9
pubmed: 26178762
Pathol Annu. 1986;21 Pt 1:173-250
pubmed: 3510415
J Surg Res. 2011 May 15;167(2):267-72
pubmed: 19783007
Ann Otol Rhinol Laryngol. 1975 Nov-Dec;84(6):793-803
pubmed: 1200569
World J Surg. 2007 Nov;31(11):2184-91
pubmed: 17721721
Head Neck. 2015 Sep;37(9):1319-25
pubmed: 24828891
Ann Surg Oncol. 2011 Aug;18(8):2310-7
pubmed: 21336511
J Natl Compr Canc Netw. 2017 Jun;15(6):761-770
pubmed: 28596256
Otolaryngol Clin North Am. 1998 Aug;31(4):671-86
pubmed: 9687328
Urol Oncol. 2017 Apr;35(4):151.e1-151.e7
pubmed: 28139370
Oncotarget. 2017 Jun 7;8(45):79462-79468
pubmed: 29108325
Chin Med J (Engl). 2013 Nov;126(21):4139-44
pubmed: 24229687
World J Surg. 2012 May;36(5):1096-101
pubmed: 22382768
Head Neck. 1998 Jan;20(1):16-21
pubmed: 9464947
Am J Surg. 1964 Oct;108:500-4
pubmed: 14211437
Br J Cancer. 2013 Oct 15;109(8):2087-95
pubmed: 24064974
Oral Oncol. 2014 Jan;50(1):59-64
pubmed: 24161464
Otolaryngol Head Neck Surg. 2003 Feb;128(2):185-90
pubmed: 12601312